NEW YORK (

TheStreet

) --

CHANGE IN RATINGS

Amylin Pharmaceuticals

( AMLN) upgraded at Citigroup from Hold to Buy. $27 price target. Remain optimistic that the FDA will ultimately approve LAR.

Amylin Pharmaceuticals

( AMLN) price target raised at Barclays $2 to $24 on approval of drug Victoza. 2009 and 2010 EPS estimates set at -$1.25 and -$0.35, respectively. Maintain Overweight rating.

Arena Resources

(SYMBOL)

upgraded at UBS from Neutral to Buy. $46 price target. Stock is down 10% year-to-date, but should exceed better-than-expected production growth.

Anixter

(AXE) - Get Report

downgraded at Credit Suisse to Underperform from Neutral as underlying business is flat, and earnings expectations are weak. $36 price target. 2009 and 2010 EPS estimates set at $2.27 and $2.84, respectively.

Continental Resources

(CLR) - Get Report

upgraded at UBS from Neutral to Buy. $46 price target. Valuation call, as the stock is down 15% in recent weeks. Company also has a strong balance sheet.

Celestica

(CLS) - Get Report

upgraded at Credit Suisse to Outperform from Neutral as checks suggest near-term and long-term trends are improving. Company has excess cash. Price target jumped to $11.50 from $9.50.

CNX Gas

( CXG) upgraded at UBS from Neutral to Buy. $34 price target. Reserves are up 34% year-over-year.

Crimson Exploration

( CXPO) initiated at Barclays with an Overweight rating and $8 price target. Drilling results in the Haynesville Shale will drive shares. 2009 and 2010 EPS estimates set at -$1.45 and -$0.20, respectively.

Eaton

(ETN) - Get Report

target, estimate raised at Barclays. Barclays increased ETN price target to $69 from $62 after 4Q09 results beat. 2010 EPS estimate lifted to $4.05 from $3.55. Maintain Equal Weight rating.

Eaton

(ETN) - Get Report

estimates, target raised at UBS. ETN estimates were increased through 2011. Company has improving demand visibility. Sell rating and new $56 price target.

Johnson Controls

(JCI) - Get Report

downgraded at UBS. JCI was downgraded from Buy to Neutral. Valuation call, based on a $32 price target. Estimates have largely caught up with the company's earnings potential.

Kraton

(KRA) - Get Report

initiated at Credit Suisse with an Outperform rating and $19 price target. World's leading producer of Styrenic Block Copolymers. 2010 and 2011 EPS estimates set at $1.74 and $1.79, respectively.

Limited Brands

(LTD)

upgraded at BMO to Outperform. $25 price target. Operating profits appear to be accelerating at Victoria's Secret.

Lexmark International

(SYMBOL)

upgraded at Barclays to Overweight from Equal Weight on cost cutting. Price target raised to $34 from $26. 2009 and 2010 EPS estimates set at $2.75 and $2.80, respectively.

Plexus

(PLXS) - Get Report

upgraded at Credit Suisse to Outperform from Neutral on improved outlook. Price target surged to $42 from $27. 2010 and 2011 EPS estimates set at $2.08 and $2.55, respectively.

Plains Exploration

(PXP)

downgraded at Morgan Stanley to Equal-weight. Stock is already beginning to price in Haynesville volume growth.

Sirius XM Radio

(SIRI) - Get Report

rated new Buy at Lazard. SIRI was initiated with a Buy rating. $1 price target. Company is raising prices and costs are falling. Financial strength is also improving.

State Street

(STT) - Get Report

upgraded at Argus from Hold to Buy. $60 price target. Expectations are low, and sales could recover in capital markets once again.

STOCK COMMENTS / EPS CHANGES

Apple

(AAPL) - Get Report

target, estimates raised at Credit Suisse. AAPL price target to $275 from $250 after posting a solid quarter. 2010 and 2011 EPS estimates set at $11.54 and $12.44, respectively. Outperform rating.

Apple

(AAPL) - Get Report

target, estimates higher at Barclays. AAPL target $5 to $265 after strong 1Q10 results. 2010 and 2011 EPS estimates raised to $11.60 and $12.75, respectively. Maintain Overweight rating.

Apple

(AAPL) - Get Report

estimates, target increased at Goldman. AAPL estimates were boosted through 2011. Higher Mac sales offset lower iPod unit volume. Neutral rating and new $230 price target.

Amgen

(AMGN) - Get Report

estimates lowered at Goldman through 2012. Company is seeing lower sales. Buy rating and $67 price target.

Atheros

( ATHR) estimates, target raised at FBR. Shares of ATHR now seen reaching $39. Estimates also increased, to reflect market share gains. Market Perform rating.

Cephalon

( CEPH) numbers upped at UBS. CEPH estimates were increased through 2010. Provigil price hike is paying off. Buy rating and new $72 price target.

Quest Diagnostics

(DGX) - Get Report

numbers increased at Goldman. Shares of DGX now seen reaching $55. Estimates also raised, because of an expected stock buyback and improving debt collection trends. Sell rating.

Halliburton

(HAL) - Get Report

estimates, target boosted at Citigroup. Shares of HAL now seen reaching $40. Estimates also raised, because of a recovery in North America. Buy rating.

Hershey

(HSY) - Get Report

added to Conviction Sell List at Goldman. $32 price target. See below-consensus growth because of higher input costs and increased competition.

McDonald's

(MCD) - Get Report

estimates, target raised at UBS. Shares of MCD now seen reaching $72. Estimates also boosted, as the company appears to be gaining market share. Buy rating.

Texas Instruments

(TXN) - Get Report

estimates upped at FBR. TXN estimates were increased through 2011. Company boosted guidance, and is likely taking market share. Outperform rating.

VMWare

(VMW) - Get Report

price target higher at Credit Suisse. VMW price target improved to $34.50 from $28.50 on solid 4Q09 results. 2010 and 2011 EPS estimates set at $1.14 and $1.26, respectively. Maintain Underperform rating.

VMware

(VMW) - Get Report

estimates, target boosted at Goldman. Shares of VMW now seen reaching $49. Estimates also upped, to reflect increased IT spending, especially in servers. Neutral rating.

Zions Bancorporation

(ZION) - Get Report

estimates cut at UBS. ZION estimates were lowered through 2011. Company is facing higher security losses and profitability will likely be pushed out. Sell rating and $10 price target.

This article was written by a staff member of TheStreet.com.